Christine P Limonte1,2, Leila R Zelnick3,4, John Ruzinski4, Andrew N Hoofnagle3,5, Ravi Thadhani6, Michal L Melamed7, I-Min Lee8,9, Julie E Buring8,9, Howard D Sesso8,9, JoAnn E Manson8,9, Ian H de Boer3,4,10. 1. Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA, USA. climonte@uw.edu. 2. Kidney Research Institute, University of Washington, Seattle, WA, USA. climonte@uw.edu. 3. Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA, USA. 4. Kidney Research Institute, University of Washington, Seattle, WA, USA. 5. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. 6. Office of the Chief Academic Officer, Partners HealthCare, Boston, MA, USA. 7. Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. 8. Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 9. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 10. Puget Sound VA Healthcare System, Seattle, WA, USA.
Abstract
AIMS/HYPOTHESIS: Interventions that reduce inflammation may delay progression of microvascular and macrovascular complications in diabetes. We examined the effects of vitamin D3 and/or n-3 fatty acid supplementation vs placebo on 5 year changes in serum inflammatory and cardiac biomarkers in adults with type 2 diabetes. METHODS: This study reports pre-specified secondary outcomes of the Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease, in which 1312 US adults with type 2 diabetes and without known cardiovascular disease, malignancy, or end-stage kidney disease were randomised using computer-generated random numbers in blocks of eight to vitamin D3 (2000 IU/day) vs placebo and n-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]; 1 g/day) vs placebo in a 2 × 2 factorial design. Participants, examiners, and researchers assessing outcomes were blinded to intervention assignment. We measured serum IL-6, high-sensitivity C-reactive protein (hsCRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) at baseline and after 2 and 5 years. RESULTS: A total of 333 participants were randomised to vitamin D3 and placebo n-3 fatty acids, 289 to n-3 fatty acids and placebo vitamin D3, 370 to vitamin D3 and n-3 fatty acids, and 320 to 2 placebos; 989 (75%) and 934 (71%) participants returned blood samples at 2 and 5 years, respectively. Participants had a mean age of 67.6 years (46% women). Overall, baseline geometric means of IL-6, hsCRP and NT-proBNP were 1.2 pg/ml, 1.9 mg/l and 262 ng/l, respectively. After 5 years, mean IL-6 and hsCRP remained within 6% of their baseline values while mean NT-proBNP increased by 55% overall. Compared with placebo, participants assigned to vitamin D3 had a 1.24-fold greater increase in NT-proBNP over 5 years (95% CI 1.09, 1.41; p = 0.003), while IL-6 and hsCRP did not have a significant difference in change. Comparing n-3 fatty acids with placebo, there was no significant difference in change in IL-6, hsCRP or NT-proBNP. No heterogeneity was observed in subgroup analyses accounting for baseline eGFR, urine albumin to creatinine ratio, initial biomarker concentration, 25-hydroxyvitamin D level or EPA+DHA index. CONCLUSIONS/ INTERPRETATION: Among adults with type 2 diabetes, supplementation with vitamin D3 or n-3 fatty acids did not reduce IL-6, hsCRP or NT-proBNP over 5 years. TRIAL REGISTRATION: ClinicalTrials.gov NCT01684722 FUNDING: The study was funded by grant R01DK088762 from the National Institute of Diabetes and Digestive and Kidney Diseases. Graphical abstract.
AIMS/HYPOTHESIS: Interventions that reduce inflammation may delay progression of microvascular and macrovascular complications in diabetes. We examined the effects of vitamin D3 and/or n-3 fatty acid supplementation vs placebo on 5 year changes in serum inflammatory and cardiac biomarkers in adults with type 2 diabetes. METHODS: This study reports pre-specified secondary outcomes of the Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease, in which 1312 US adults with type 2 diabetes and without known cardiovascular disease, malignancy, or end-stage kidney disease were randomised using computer-generated random numbers in blocks of eight to vitamin D3 (2000 IU/day) vs placebo and n-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]; 1 g/day) vs placebo in a 2 × 2 factorial design. Participants, examiners, and researchers assessing outcomes were blinded to intervention assignment. We measured serum IL-6, high-sensitivity C-reactive protein (hsCRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) at baseline and after 2 and 5 years. RESULTS: A total of 333 participants were randomised to vitamin D3 and placebo n-3 fatty acids, 289 to n-3 fatty acids and placebo vitamin D3, 370 to vitamin D3 and n-3 fatty acids, and 320 to 2 placebos; 989 (75%) and 934 (71%) participants returned blood samples at 2 and 5 years, respectively. Participants had a mean age of 67.6 years (46% women). Overall, baseline geometric means of IL-6, hsCRP and NT-proBNP were 1.2 pg/ml, 1.9 mg/l and 262 ng/l, respectively. After 5 years, mean IL-6 and hsCRP remained within 6% of their baseline values while mean NT-proBNP increased by 55% overall. Compared with placebo, participants assigned to vitamin D3 had a 1.24-fold greater increase in NT-proBNP over 5 years (95% CI 1.09, 1.41; p = 0.003), while IL-6 and hsCRP did not have a significant difference in change. Comparing n-3 fatty acids with placebo, there was no significant difference in change in IL-6, hsCRP or NT-proBNP. No heterogeneity was observed in subgroup analyses accounting for baseline eGFR, urine albumin to creatinine ratio, initial biomarker concentration, 25-hydroxyvitamin D level or EPA+DHA index. CONCLUSIONS/ INTERPRETATION: Among adults with type 2 diabetes, supplementation with vitamin D3 or n-3 fatty acids did not reduce IL-6, hsCRP or NT-proBNP over 5 years. TRIAL REGISTRATION: ClinicalTrials.gov NCT01684722 FUNDING: The study was funded by grant R01DK088762 from the National Institute of Diabetes and Digestive and Kidney Diseases. Graphical abstract.
Authors: Bonnie Ky; Justine Shults; Martin G Keane; Martin St John Sutton; Myles Wolf; Harold I Feldman; Peter P Reese; Cheryl A Anderson; Raymond R Townsend; Rajat Deo; Joan Lo; Crystal Gadegbeku; Dean Carlow; Michael J Sulik; Mary B Leonard Journal: Circ Heart Fail Date: 2013-06-07 Impact factor: 8.790
Authors: Ravi Thadhani; Evan Appelbaum; Yili Pritchett; Yuchiao Chang; Julia Wenger; Hector Tamez; Ishir Bhan; Rajiv Agarwal; Carmine Zoccali; Christoph Wanner; Donald Lloyd-Jones; Jorge Cannata; B Taylor Thompson; Dennis Andress; Wuyan Zhang; David Packham; Bhupinder Singh; Daniel Zehnder; Amil Shah; Ajay Pachika; Warren J Manning; Scott D Solomon Journal: JAMA Date: 2012-02-15 Impact factor: 56.272
Authors: Francesca L Crowe; Rasiah Thayakaran; Neil Gittoes; Martin Hewison; G Neil Thomas; Robert Scragg; Krishnarajah Nirantharakumar Journal: J Steroid Biochem Mol Biol Date: 2019-09-18 Impact factor: 4.292
Authors: Sangita Choudhury; Soochan Bae; Qingen Ke; Ji Yoo Lee; Sylvia S Singh; René St-Arnaud; Federica Del Monte; Peter M Kang Journal: PLoS One Date: 2014-09-30 Impact factor: 3.240
Authors: Camille M Mba; Albert Koulman; Nita G Forouhi; Stephen J Sharp; Fumiaki Imamura; Kerry Jones; Sarah R Meadows; Felix Assah; Jean Claude Mbanya; Nick J Wareham Journal: Nutr Diabetes Date: 2022-07-29 Impact factor: 4.725